A new surgical technique known as a neurosafe is giving new hope to men undergoing prostate cancer, doubling the possibility of preserving erectile task without compromising on the treatment of cancer, saying that researchers say. In a study published on March 24 in Lancet Oncology, a detailed new method helps surgeons to maintain delicate veins running with the outer layers of prostate, which plays an important role in erectile task. In addition to preserving these nerves, the technique involves a real -time pathological assessment to ensure that all cancer tissues have been removed, reducing the risk of repetition.

How neurosaff works

Traditional prostate cancer surgery is a significant risk of impotence and incontinence, two common side effects that can affect the quality of life of the patient. While robotic-assisted surgery has improved accuracy, one of the major challenges of surgeons is determining whether the veins can spare cancer cells. This uncertainty often motivates doctors to misinformation in favor of caution, sacrifice the veins to completely remove the veins.

The surgeons address this challenge by allowing surgeons to examine the remaining cancer cells during operation. The process involves removing the prostate gland, while preserving more and more nerve tissue as possible. Once the prostate extract, it is flash-frozen, and tissue samples are immediately analyzed by a pathologist. If the cancer cells are detected near the veins, the surgeons may decide to remove the additional tissue. If no cancer is found in nerve areas, the operation increases with the veins.

This real -time decision -making process ensures that the patient receives the most effective cancer treatment, maximizing the possibility of maintaining erectile function.

Clinical test results show promising results

The effectiveness of neurosafe was tested in a clinical test in five hospitals in the United Kingdom. In the study, 344 men were diagnosed with prostate cancer which were prescribed to remove prostate. Half of the participants performed standard surgery, while the other half found neurosafe technology.

A year after surgery, 39 percent of men undergoing neurosafe had either or mild erectile dysfunction, while compared to only 23 percent of standard surgery. Severe erectile dysfunction was seen only in 38 percent of neurosaff patients, while 56 percent of traditional surgery reported serious losses.

The technology did not increase the risk of incontinence, and patients who experienced urinary control issues were rapidly recovered with neurosaff compared to standard surgery.

Expert insight and future possibilities

Urologist, a advisor at University College London Hospital and a prominent researcher in the study, Dr. Greg Shaw emphasized the benefits of neurosafe, stating, “Our results suggest that using neurosafe, almost twice as many men do not face erectile dysfunction defects after prostate surgery.

Fellow, a research from University College London. Ricardo Almeeda-Magana said that neurosaf provides a level of certainty that lacks traditional methods. He said, “Surgeons usually rely on MRI scan, digital rectal examination, and biopsy results whether nerves to leave.

However, experts have warned that neurosafe may not be suitable for all patients. “Many men may already have nerve-spacked surgery using standard robotic techniques,” Shaw said. “But for young patients or those who do not qualify for the processes of nerve-spending normally, this method gives them a better chance to maintain their quality of life.”

Necessity for further research

While the initial conclusions are promising, researchers emphasized that further studies are required to assess long -term cancer results of patients treated with neurosafe. Continuous monitoring and additional tests will help determine the durability of its benefits in preventing the recurrence of cancer.

For now, the introduction of neurosaff represents an important step in prostate cancer surgery, leading to more expectation of complete recovery with less life-changing side effects.

Now get the latest news with health and braking news and top headlines worldwide.